Health Catalyst Inc · Q4 2022 earnings

Briefing

Achieved strong performance, exceeding revenue and Adjusted EBITDA guidance for Q4 2022.

Health Catalyst reported strong Q4 2022 results, exceeding revenue and Adjusted EBITDA guidance. The company also announced the appointment of Matthew Kolb to its Board of Directors and a deepened investment from Carle Health.

• Achieved strong performance across the business in Q4 2022, exceeding the mid-point of quarterly guidance for both revenue and Adjusted EBITDA.
• Adjusted EBITDA outperformed the mid-point of the original full year guidance provided entering 2022.
• Matthew Kolb, Executive Vice President and Chief Operating Officer of Carle Health, will be joining the Health Catalyst Board of Directors, effective July 1, 2023.
• Carle Health has made the decision to deepen its long-term investment in Health Catalyst with a meaningful purchase on the open market of Health Catalyst’s common stock.

Headline financials

Revenue & EPS history

For the first quarter of 2023, Health Catalyst expects total revenue between $70.3 million and $72.3 million, and Adjusted EBITDA between $1.0 million and $2.5 million. For the full year of 2023, the company expects total revenue between $290 million and $295 million, and Adjusted EBITDA between $9.0 million and $11.0 million.